Dr. Rajasundaram Gets Helpful, Hopeful News for Bone Marrow Transplant Patients in India

Leukemia can be a terrifying diagnosis for the more than 60,000 U.S. patients who are told they've this blood cancer every year. For patients with For patients with certain kinds of leukemia, the best chance they have for a cure is to receive a massive dose of radiation and chemotherapy that kills their hematopoietic stem cells (HSCs), the cells responsible for making new blood, and then acquire new HSCs from a healthy donor.

Patients have to go through HSC transplants every day to within the protected confines of a clinic gauge successful engraftment, searching for the presence of immune cells called neutrophils, explains Dr. Rajasundaram, Best Surgical Oncologist Surgeon at Global Hospital Chennai, India. As you head into week 3 post-transplant and a patient's cell counts remain at zero, all begins to get nervous,"

Dr. Rajasundaram top surgical oncologist in India says. The longer a patient goes without an immune system, the better the chance that they'll develop life-threatening infections. Until recently, Dr. Rajasundaram says, there has been no way beyond those daily blood tests to assess whether the newly infused cells have survived and started to grow early healthy cells in the bone marrow, a process called engraftment.

The study recorded an investigational imaging test called 18F-fluorothymidine (18F-FLT). Its radio labeled analogue of thymidine, a natural issue of DNA. Research has shown that this compound is included into just 3 white blood cellular types, which includes HSCs. because it's radioactive, it may be seen on various types of common scientific imaging tests, inclusive of positron emission tomography (pet) and computed tomography (CT) scans. For that reason, after infusion, the newly infused developing immune system and marrow is readily visible. To see if this compound can simply and appropriately visualize transplanted HSCs, Dr. Rajasundaram and colleagues tested it on 23 patients with various forms of high-risk leukemia. After theses patients’ recieved total-body irradiation to destroy their own HSCs, they received donor HSCs from relatives or strangers. One day before they were infused with these donor cells, and then at five or nine days, 28 days, and one year after transplantation, the patients underwent imaging with the novel PET/and CT scan imaging platform.

Each of those patients had a successful engraftment, reflected in blood assessments 2 to 4 weeks after their HSC transplants. By one year, most of the new HSCs were focused inside the bones that make up the trunk of the body, including the hip, where most biopsies to assess marrow function take place.

Interestingly, notes Dr. Rajasundaram, this pathway is the same one that HSCs take in the fetus when they first form. Notwithstanding the truth that experimental model research had formerly advised that transplanted HSCs travel the same route little was known about whether HSCs in human patients followed suit. The study at additionally demonstrated that the radiation in 18F-FLT did no longer adversely affect engraftment. Additionally, images could identify success of their engraftments potentially weeks faster than they would have through traditional blood tests--a definite advantage to this technique.

"Through the images we took, these sufferers ought to see the new cells developing in their bodies," Dr. Rajasundaram top surgical oncologist in India says. "They loved that."

And importantly, if the new healthful cells do not grow, this take a look at could sign this failure to doctors, enabling rapid mobilization of new cells to avert life-threatening infections and help us save lives after transplants at high risk of graft failure. "What occurs with HSCs always has been a mystery," Dr. Rajasundaram says. "Now we are able to begin to open that black box."

Visit website for more details: Leukemia can be a terrifying diagnosis for the more than 60,000 U.S. patients who are told they've this blood cancer every year. For patients with For patients with certain kinds of leukemia, the best chance they have for a cure is to receive a massive dose of radiation and chemotherapy that kills their hematopoietic stem cells (HSCs), the cells responsible for making new blood, and then acquire new HSCs from a healthy donor.

Patients have to go through HSC transplants every day to within the protected confines of a clinic gauge successful engraftment, searching for the presence of immune cells called neutrophils, explains Dr. Rajasundaram, Best Surgical Oncologist Surgeon at Global Hospital Chennai, India. As you head into week 3 post-transplant and a patient's cell counts remain at zero, all begins to get nervous,"

Dr. Rajasundaram top surgical oncologist in India says. The longer a patient goes without an immune system, the better the chance that they'll develop life-threatening infections. Until recently, Dr. Rajasundaram says, there has been no way beyond those daily blood tests to assess whether the newly infused cells have survived and started to grow early healthy cells in the bone marrow, a process called engraftment.

The study recorded an investigational imaging test called 18F-fluorothymidine (18F-FLT). Its radio labeled analogue of thymidine, a natural issue of DNA. Research has shown that this compound is included into just 3 white blood cellular types, which includes HSCs. because it's radioactive, it may be seen on various types of common scientific imaging tests, inclusive of positron emission tomography (pet) and computed tomography (CT) scans. For that reason, after infusion, the newly infused developing immune system and marrow is readily visible. To see if this compound can simply and appropriately visualize transplanted HSCs, Dr. Rajasundaram and colleagues tested it on 23 patients with various forms of high-risk leukemia. After theses patients’ recieved total-body irradiation to destroy their own HSCs, they received donor HSCs from relatives or strangers. One day before they were infused with these donor cells, and then at five or nine days, 28 days, and one year after transplantation, the patients underwent imaging with the novel PET/and CT scan imaging platform.

Each of those patients had a successful engraftment, reflected in blood assessments 2 to 4 weeks after their HSC transplants. By one year, most of the new HSCs were focused inside the bones that make up the trunk of the body, including the hip, where most biopsies to assess marrow function take place.

Interestingly, notes Dr. Rajasundaram, this pathway is the same one that HSCs take in the fetus when they first form. Notwithstanding the truth that experimental model research had formerly advised that transplanted HSCs travel the same route little was known about whether HSCs in human patients followed suit. The study at additionally demonstrated that the radiation in 18F-FLT did no longer adversely affect engraftment. Additionally, images could identify success of their engraftments potentially weeks faster than they would have through traditional blood tests--a definite advantage to this technique.

"Through the images we took, these sufferers ought to see the new cells developing in their bodies," Dr. Rajasundaram top surgical oncologist in India says. "They loved that."

And importantly, if the new healthful cells do not grow, this take a look at could sign this failure to doctors, enabling rapid mobilization of new cells to avert life-threatening infections and help us save lives after transplants at high risk of graft failure. "What occurs with HSCs always has been a mystery," Dr. Rajasundaram says. "Now we are able to begin to open that black box."

Visit website for more details: https://www.indiacancersurgerysite.com/consult-dr-rajasundaram-best-onco-surgeon-global-hospital-chennai.html